MAM
AMRI

Martingale Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Martingale Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-16,803
Closed -$371K – 915
2014
Q3 		$371K Buy
+16,803
New +$344K 0.01% 722

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Martingale Asset Management's AMRI Position: Q4 2014 in Review

Martingale Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q4 2014, closing a stake of 16,803 shares — an estimated $371K sold.

Martingale Asset Management first reported a position in AMRI in Q3 2014 and held it in 1 quarter. The position peaked at $371K in Q3 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q4 2014.

  • Martingale Asset Management reported no remaining Albany Molecular Research Inc position as of Q4 2014 after selling out during the quarter.
  • Martingale Asset Management sold 16,803 Albany Molecular Research Inc shares in Q4 2014, an estimated $371K.
  • Martingale Asset Management first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 1 quarter.
  • Martingale Asset Management's Albany Molecular Research Inc position peaked at $371K in Q3 2014.
  • 132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2014.

Based on Martingale Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.